ReviewJournal of neurochemistry2026
Neuroinflammation and Graft Survival in Pluripotent Stem Cell-Derived Therapies for the Central Nervous System.
Review in Journal of neurochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recently, Japan conditionally approved the first cell transplantation therapy for a central nervous system disorder using induced pluripotent stem cells as the source of dopaminergic progenitors to treat Parkinson's disease. This milestone was achieved almost 40 years after the first cell therapy trial for Parkinson's disease in Lund, Sweden, and 18 years after the first clinical trial using oligodendrocyte progenitors derived from pluripotent stem cells for spinal cord injury. In this review, we update the current state of development of cell therapies based on pluripotent stem cells for diseases of the central nervous system and discuss the potential effects of neuroinflammation on these cell therapies. Focusing on Parkinson's disease, we summarize data showing the functional relevance of tumor necrosis factor-alpha for the differentiation and viability of pluripotent stem cell-derived dopaminergic progenitors and its dual effects on endogenous dopaminergic neurons, as presented at the Second Meeting of the Latin American Glia Club, held April 7-9, 2025, in Buenos Aires, Argentina. In addition, we propose areas of cell transplantation in Parkinson's disease in which research efforts could be focused and present a cautionary note on the use of non-selective anti-tumor necrosis factor-α therapies alongside pluripotent stem cell-derived dopaminergic progenitor transplantation. Finally, we provide an in-depth list of TNF receptor agonists and antagonists and specific TNF-mediated cell-death inhibitors and discuss their properties as possible candidates for increasing dopaminergic progenitor survival after transplantation in patients with Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.